Bio-Rad Laboratories (NYSE:BIO.B) Sees Large Volume Increase – Still a Buy?

Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO.B) saw unusually-strong trading volume on Wednesday . Approximately 100 shares were traded during trading, an increase of 1,329% from the previous session’s volume of 7 shares.The stock last traded at $312.75 and had previously closed at $310.70.

Bio-Rad Laboratories Stock Up 0.7%

The firm has a fifty day moving average price of $310.78 and a 200 day moving average price of $284.15. The firm has a market capitalization of $8.44 billion, a price-to-earnings ratio of -12.87 and a beta of 1.01. The company has a current ratio of 5.44, a quick ratio of 3.94 and a debt-to-equity ratio of 0.18.

Bio-Rad Laboratories (NYSE:BIO.B) last issued its quarterly earnings data on Wednesday, October 29th. The company reported $2.26 earnings per share (EPS) for the quarter. The firm had revenue of $653.00 million during the quarter. Bio-Rad Laboratories had a positive return on equity of 4.19% and a negative net margin of 26.43%.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc is a global provider of innovative products and systems that serve the life science research and clinical diagnostics markets. The company operates through two primary segments: Life Science, which delivers instruments, consumables and software for research applications, and Clinical Diagnostics, which offers quality control materials and reagent systems for blood typing, immunology and molecular testing. Bio-Rad’s product portfolio supports a wide range of applications, including protein analysis, gene expression, cell biology and digital PCR.

In the Life Science segment, Bio-Rad develops and markets technologies such as electrophoresis and imaging systems, chromatography instruments, laboratory consumables and software platforms that streamline experimental workflows.